Patients Undergoing Revision Hip Arthroscopy With Labral Reconstruction or Augmentation Demonstrate Favorable Patient Reported Outcomes: A Systematic Review

Purpose To review current literature evaluating patient-reported outcomes (PROs) and survivorship in patients undergoing revision hip arthroscopy with labral reconstruction or augmentation. Methods A systematic review was performed with the following keywords: (revision) AND (hip OR femoroacetabular impingement) AND (arthroscopy OR arthroscopic) AND (reconstruction OR augmentation OR irreparable). PubMed, Cochrane Trials, and Scopus were queried in October 2022 using the criteria established in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). Studies were included if they involved patients undergoing revision hip arthroscopy with labral reconstruction or augmentation and reported pre- and postoperative PROs at minimum 2-year follow-up. Only original research articles were included. Survivorship was defined as a non-conversion to THA. Outcomes present in three or more studies underwent further statistical analysis with forest plots. Heterogeneity of studies was evaluated using the I2 statistic. Results Five studies were reviewed including 359 revision hip arthroscopies (335 with complete follow-up) with a follow-up that ranged from 2.2 - 5.2 years. Four studies reported on outcomes after revision labral reconstruction and one study reported on labral augmentation. Two out of five included studies evaluated for statistical significance between pre- and post-operative outcomes. Three out of five studies reported a rate of at least 70% for achieving MCID in at least one PRO. At minimum 2-year follow-up, survivorship ranged from 93.5% - 100%. Conclusion Patients that underwent revision hip arthroscopy with labral reconstruction or augmentation demonstrated improvement in PROs with mixed rates of achieving clinical benefit and rates of survivorship at minimum 2-year follow-up ranging from 93.5% - 100%. Study Design Systematic Review of Level III to IV studies, Level of Evidence IV To review current literature evaluating patient-reported outcomes (PROs) and survivorship in patients undergoing revision hip arthroscopy with labral reconstruction or augmentation. A systematic review was performed with the following keywords: (revision) AND (hip OR femoroacetabular impingement) AND (arthroscopy OR arthroscopic) AND (reconstruction OR augmentation OR irreparable). PubMed, Cochrane Trials, and Scopus were queried in October 2022 using the criteria established in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). Studies were included if they involved patients undergoing revision hip arthroscopy with labral reconstruction or augmentation and reported pre- and postoperative PROs at minimum 2-year follow-up. Only original research articles were included. Survivorship was defined as a non-conversion to THA. Outcomes present in three or more studies underwent further statistical analysis with forest plots. Heterogeneity of studies was evaluated using the I2 statistic. Five studies were reviewed including 359 revision hip arthroscopies (335 with complete follow-up) with a follow-up that ranged from 2.2 - 5.2 years. Four studies reported on outcomes after revision labral reconstruction and one study reported on labral augmentation. Two out of five included studies evaluated for statistical significance between pre- and post-operative outcomes. Three out of five studies reported a rate of at least 70% for achieving MCID in at least one PRO. At minimum 2-year follow-up, survivorship ranged from 93.5% - 100%. Patients that underwent revision hip arthroscopy with labral reconstruction or augmentation demonstrated improvement in PROs with mixed rates of achieving clinical benefit and rates of survivorship at minimum 2-year follow-up ranging from 93.5% - 100%.